Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 150 /hr

★★★★★

☆☆☆☆☆

Hire Desa Rae S.

United States

USD 150 /hr

Freelance Clinical Consultant & Project Director with 15+ Years of Experience | Immuno-Oncology |

Profile Summary

Clinical Operations Director with over 15 years of industry experience in the early (seed) and late-stage biotech sector, as well as the clinical trial central laboratory vendor space. Proven success in vendor selection, contract negotiation and financial budgeting and forecasting for clinical trial programs. Extensive experience in developing and managing clinical trials at IND filing, start-up and through close out in Phase I/Ib/II Oncology and Immuno-Oncology

Subject Matter Expertise

• ☆ Financial Modeling
• ☆ Drug Development
• ☆ Small Molecule Drug Development
• ☆ Preclinical Research
• ☆ Investigational New Drug (IND) Application Consulting
• ☆ Drug Efficacy Testing
• ☆ Clinical Trials
• ☆ Clinical Trial Design
• ☆ Clinical Trial Site Selection & Monitoring
• ☆ Clinical Trials Data Analysis
• ☆ Oncology
• ☆ Immunotherapy
• ☆ Business Operations
• ☆ Business Strategy
• ☆ Data-Driven Decision Making
• ☆ Entrepreneurship
• ☆ Project Management

Services

• Writing
• Consulting

Writing Clinical Trial Documentation, Medical Writing

Consulting Operations Consulting

Work Experience

Executive Vice President, Clinical Operations

Cyncado Therapeutics

January 2025 - Present

Vice President, Clinical Operations

AION Healthspan, Inc.

March 2024 - Present

Senior Director, Clinical Operations

Portage Development Services

July 2022 - Present

Education

Masters of Science

Rochester Institute of Technology, Rochester, NY

September 2009 - June 2011

Bachelors in Biomedical Sciences

Rochester Institute of Technology, Rochester, NY

September 2005 - June 2009

Certifications

• Medidata Rave EDC Certified Clinical Research Coordinator

  Medidata

  September 2022 - Present

Publications

CONFERENCE PAPER

Desa Rae Stanton-Pastore, Sumit Subudhi, Gerald S Falchook, Mohamad A Salkeni, Anthony El-Khoueiry, Jaspreet Grewal, William Tester, Russell Pachynski, Samik Upadhaya, Ana Rosa Saez Ibanez, et al. (2023). 759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors . Regular and Young Investigator Award Abstracts.

JOURNAL ARTICLE

Nicholas Coupe, David J. James Pinato, Justin P. Fairchild, Desa Rae Electa Pastore, Steven Innaimo, David Thompson, Uzi Gileadi, Robert A. Kramer, Ian B. Walters, Mark R. Middleton (2023). IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC) . Journal of Clinical Oncology.

Desa Rae E. Pastore, Kasim Mookhtiar, Brian Schwartz, Sushant Kumar, Ranganayaki Nagaraj, Ashwinkumar V. Meru (2022). Abstract 3454: Adenosine receptor antagonists A2AR (TT-10) and A2BR (TT-4) demonstrate anti-tumor activity in 4T1-induced syngeneic breast cancer mouse model . Cancer Research.

Sushant Kumar, Kasim Mookhtiar, Desa Rae Pastore, Brian Schwartz, Vijay Reddy (2021). Abstract P042: Phase I/II first-in-human study of TT-10 (A2AB inhibitor) as a single agent in subjects with advanced selected solid tumors . Molecular Cancer Therapeutics.

Desa Rae Pastore, Sushant Kumar, Brian Schwartz, Kasim Mookhtiar, Vijay Reddy (2021). 257 Combination of adenosine antagonists A2AR (TT-10) and A2BR (TT-4) with checkpoint inhibitors demonstrate anti-tumor activity in CT-26 murine colon tumor allograft model . Journal for ImmunoTherapy of Cancer.

Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, et al. (2021). A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer . Clinical Cancer Research.

Jonathan W. Goldman, Terrence L. Fisher, Elizabeth Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Andreas Schröeder, Kevin Chin, Michael Shafique, et al. (2020). Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC . Cancer Research.

Elizabeth E. Evans, Gregory B. Lesinski, Terrence L. Fisher, Crystal Mallow, Brian Olson, Paul E. Clavijo, John E. Leonard, Desa Rae Pastore, Ernest S. Smith, Maurice Zauderer, et al. (2020). Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors . Clinical Cancer Research.

Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, Joseph Thaddeus Beck, et al. (2020). Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC . Journal of Clinical Oncology.

C. Steuer, G.B. Lesinski, E.E. Evans, T.L. Fisher, C. Mallow, B. Olson, D.R. Pastore, J.E. Leonard, E. Smith, M. Zauderer, et al. (2020). Integrated Biomarker Study of Pepinemab in Combination with Nivolumab or Ipilimumab to Evaluate Immune Cell Composition of TME in Patients with Head and Neck Squamous Cell Carcinoma and Other Solid Tumors . International Journal of Radiation Oncology*Biology*Physics.

Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, J. Thaddeus Beck, et al. (2020). Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies . Journal of Clinical Oncology.

Elizabeth E. Evans, Terrence L. Fisher, Holm Bussler, Crystal Mallow, Christine Reilly, Sebold Torno, Desa Rae Pastore, Maria Scrivens, Alan Howell, Leslie Balch, et al. (2019). Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies . Cancer Research.

Elizabeth E. Evans, Terrence L. Fisher, Holm Bussler, Crystal Mallow, Christine Reilly, Sebold Torno, Desa Rae Pastore, Maria Scrivens, Alan Howell, Leslie Balch, et al. (2019). Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies . Cancer Research.

Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröeder, Kevin Chin, et al. (2019). Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC . Cancer Research.

Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröeder, Kevin Chin, et al. (2019). Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC . Cancer Research.

Gregory B. Lesinski, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Maurice Zauderer, Conor Steuer, Nabil F. Saba, et al. (2019). Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors . Cancer Research.

Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Maurice Zauderer, Andreas Schröder, Kevin M. Chin, et al. (2019). Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC . Journal of Clinical Oncology.